Clover Health Investments (CLOV, Health insurers) Stock Valuation & Fair Value
Trading above its usual valuationClover Health Investments (CLOV, Health insurers) trades at a current P/E of 90.7, about 40% above its historical normal valuation, with a forward growth estimate of 60.6% and a PEG of 1.50. Analysts' one-year estimates have been hit 25% of the time. Priced at its historical normal P/E of 65.0 on the same blended earnings, the 2026-11-06 close of $4.82 corresponds to about $3.45 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $4.82 at the Nov 6 close, 4.1% above the 20-day average ($4.63) and 6.2% above the 50-day ($4.54).
- RSI (14) at 56.0.
- 52-week range $1.70 to $5.41: the price is 10.9% below the high and 183.5% above the low.
The Street vs SeerForecast
Wall Street's mean price target for CLOV is $5.50 across 5 analysts, 14.1% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: trading above its usual valuation. When the two disagree, start your digging there.
Valuation flags
- No profitable year in the reported earnings on file
- Overvalued by 40%
Verdict history
tickerseer's rating moved from significantly overvalued (2026-07-31) to trading above its usual valuation (2026-11-02). New rating rules took effect in the week of 2026-10-12, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 29 readings
Frequently asked questions
Is Clover Health Investments stock overvalued?
At a current P/E of 90.7 versus its historical normal P/E of 65.0, Clover Health Investments trades about 40% above its typical valuation, with a PEG of 1.50 on 60.6% forward growth. tickerseer currently rates it trading above its usual valuation.
What is Clover Health Investments's fair value and PEG?
Clover Health Investments trades at a current P/E of 90.7 against a historical normal P/E of 65.0, a PEG of 1.50, and a forward growth estimate of 60.6%. Priced at its historical normal P/E of 65.0 on the same blended earnings, the 2026-11-06 close of $4.82 corresponds to about $3.45 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Clover Health Investments changed?
tickerseer's rating moved from significantly overvalued (2026-07-31) to trading above its usual valuation (2026-11-02). New rating rules took effect in the week of 2026-10-12, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
What is the analyst price target for Clover Health Investments?
The mean Wall Street price target for Clover Health Investments is $5.50 across 5 analysts, 14.1% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Health insurers. Create a free account to see the full analysis: the SeerAI score, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.